Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus subtilis YHX001J is a specific strain of *Bacillus subtilis*, a Gram-positive, catalase-positive bacterium commonly found in soil and the gastrointestinal tracts of humans and animals. While specific details regarding the YHX001J strain are not widely available in public literature, *Bacillus subtilis* in general is recognized as a probiotic with various beneficial effects. Its mechanism of action involves producing antimicrobial substances (such as bacitracin, surfactin, iturin, and fengycin) that inhibit pathogenic bacteria and fungi, competing with pathogens for nutrients and space (competitive exclusion), and normalizing intestinal flora. It also enhances gut microbiota by producing enzymes that improve digestion and nutrient absorption, stimulates immune responses by promoting antimicrobial peptides and gut barrier integrity, and can reduce inflammation. *Bacillus subtilis* is generally recognized as safe (GRAS) by regulatory bodies like the FDA and EFSA, making it an attractive probiotic for various clinical conditions and applications in human and animal health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bacillus subtilis YHX001J.